HK1133398A1 - Liposome formulation of mitoxantrone and method for preparation thereof - Google Patents

Liposome formulation of mitoxantrone and method for preparation thereof

Info

Publication number
HK1133398A1
HK1133398A1 HK10100560.8A HK10100560A HK1133398A1 HK 1133398 A1 HK1133398 A1 HK 1133398A1 HK 10100560 A HK10100560 A HK 10100560A HK 1133398 A1 HK1133398 A1 HK 1133398A1
Authority
HK
Hong Kong
Prior art keywords
mitoxantrone
preparation
liposome formulation
liposome
formulation
Prior art date
Application number
HK10100560.8A
Other languages
English (en)
Inventor
Chunlei Li
Jinxu Wang
Caixia Wang
Yanhui Li
Dongmin Shen
Wenmin Guo
Li Zhang
Lan Zhang
Original Assignee
Cspc Zhongqi Pharmaceutical Technology Shijiazhua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cspc Zhongqi Pharmaceutical Technology Shijiazhua filed Critical Cspc Zhongqi Pharmaceutical Technology Shijiazhua
Publication of HK1133398A1 publication Critical patent/HK1133398A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10100560.8A 2006-12-29 2010-01-20 Liposome formulation of mitoxantrone and method for preparation thereof HK1133398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101023398A CN101209243B (zh) 2006-12-29 2006-12-29 一种脂质体药物及其制备方法
PCT/CN2007/071403 WO2008080367A1 (fr) 2006-12-29 2007-12-29 Composition de liposome et son procédé de préparation

Publications (1)

Publication Number Publication Date
HK1133398A1 true HK1133398A1 (en) 2010-03-26

Family

ID=39588170

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100560.8A HK1133398A1 (en) 2006-12-29 2010-01-20 Liposome formulation of mitoxantrone and method for preparation thereof

Country Status (16)

Country Link
US (2) US20110002977A1 (zh)
EP (1) EP2123260B1 (zh)
JP (3) JP2010514708A (zh)
KR (1) KR101126629B1 (zh)
CN (1) CN101209243B (zh)
AU (1) AU2007341803B2 (zh)
BR (1) BRPI0720733A2 (zh)
CA (1) CA2673924C (zh)
CO (1) CO6190601A2 (zh)
CU (1) CU23980B1 (zh)
ES (1) ES2401526T3 (zh)
HK (1) HK1133398A1 (zh)
MX (1) MX2009007089A (zh)
MY (1) MY150670A (zh)
RU (1) RU2494729C2 (zh)
WO (1) WO2008080367A1 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
WO2010058840A1 (ja) * 2008-11-20 2010-05-27 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
AU2014200717B2 (en) * 2009-03-30 2016-02-25 Eisai R&D Management Co., Ltd. Liposome composition
US20120058178A1 (en) * 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
CN101897667B (zh) * 2009-05-26 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸多柔比星脂质体注射剂及其制备工艺
IN2012DN00570A (zh) * 2009-07-14 2015-06-12 Polypid Ltd
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
KR20130089151A (ko) * 2010-05-10 2013-08-09 마이클 에이 슈미트 치료 리포좀 및 이의 제조 및 사용 방법
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US20150283272A1 (en) * 2010-10-27 2015-10-08 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
US20140328759A1 (en) 2011-10-25 2014-11-06 The University Of British Columbia Limit size lipid nanoparticles and related methods
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
TR201908531T4 (tr) * 2012-11-20 2019-08-21 Arbutus Biopharma Corp Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
KR101503492B1 (ko) * 2013-07-03 2015-03-19 전북대학교산학협력단 지질 및 리소좀 효소를 포함하는 리포좀 캡슐 및 그 제조방법
ES2836772T3 (es) 2014-04-30 2021-06-28 Fujifilm Corp Composición liposomal y método para producirla
WO2015166985A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
RU2738365C2 (ru) 2015-11-02 2020-12-11 Фуджифилм Корпорэйшн Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина
MX2019008533A (es) * 2017-01-18 2019-12-02 Temasek Life Sciences Laboratory Ltd Liposomas hiperestabilizados aumentan el ataque direccionado a células mitóticas.
WO2018204495A1 (en) * 2017-05-02 2018-11-08 Synthetic Genomics, Inc. Nanolipoprotein particles and related compositions methods and systems for loading rna
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
CN108721644B (zh) * 2018-06-05 2021-06-08 常州金远药业制造有限公司 一种紫杉烷类药物脂质体制备方法
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN115087436A (zh) * 2020-02-10 2022-09-20 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗乳腺癌的用途
CN115279344A (zh) * 2020-03-12 2022-11-01 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN115427020A (zh) * 2020-04-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN113876711A (zh) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 一种盐酸阿霉素脂质体的制备工艺
US20230293454A1 (en) 2020-08-07 2023-09-21 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome and pegaspargase
CN115955971A (zh) * 2020-08-27 2023-04-11 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途
CN116600788A (zh) * 2020-12-15 2023-08-15 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
JP2024513965A (ja) 2021-04-16 2024-03-27 石薬集団中奇制薬技術（石家庄）有限公司 ミトキサントロン塩酸塩リポソームの応用
JP2024519172A (ja) * 2021-05-28 2024-05-08 石薬集団中奇制薬技術（石家庄）有限公司 進行固形腫瘍を治療する薬物の製造のためのミトキサントロン塩酸塩リポソームの用途
WO2023036161A1 (zh) * 2021-09-07 2023-03-16 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
WO2023207931A1 (zh) * 2022-04-26 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5169635A (en) * 1989-11-17 1992-12-08 Fuji Photo Film Co., Ltd. Photoresponsive liposome
CA2186745A1 (en) * 1994-03-28 1995-10-05 Hiroshi Kikuchi Liposome with increased retention volume
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0825852B1 (en) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
ATE238039T1 (de) * 1998-09-16 2003-05-15 Alza Corp In liposomen eingeschlossene topoisomerase inhibitoren
KR100726742B1 (ko) * 1999-07-16 2007-06-11 알자 코포레이션 동결/해동 손상에 저항성을 가진 리포좀 조성물
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
CZ20031262A3 (en) 2000-10-16 2004-03-17 Neopharm, Inc. Liposomal formulation of mitoxantrone
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
CA2506746A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7288396B2 (en) * 2003-09-11 2007-10-30 Kosan Biosciences Incorporated Biosynthetic gene cluster for leptomycins
RU2258530C1 (ru) * 2004-04-27 2005-08-20 Генкин Дмитрий Дмитриевич Способ профилактики и коррекции изменений кожи
KR101462825B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CN1242740C (zh) * 2004-08-05 2006-02-22 常州太平洋药物研究所有限公司 米托蒽醌或盐酸米托蒽醌脂质体注射剂及其制备工艺
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006298844A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソーム内に医薬化合物を内包するリポソーム含有製剤
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
EP1962805B1 (en) * 2005-12-08 2016-07-06 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US7703945B2 (en) 2006-06-27 2010-04-27 Cree, Inc. Efficient emitting LED package and method for efficiently emitting light
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20120058178A1 (en) * 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
JP5480867B2 (ja) * 2011-10-07 2014-04-23 住友ゴム工業株式会社 空気入りタイヤ

Also Published As

Publication number Publication date
CA2673924A1 (en) 2008-07-10
ES2401526T3 (es) 2013-04-22
RU2009126983A (ru) 2011-02-10
US20160235671A1 (en) 2016-08-18
US10028913B2 (en) 2018-07-24
CU23980B1 (es) 2014-01-29
CN101209243B (zh) 2010-12-08
BRPI0720733A2 (pt) 2014-01-07
MX2009007089A (es) 2009-10-08
CO6190601A2 (es) 2010-08-19
JP2015180652A (ja) 2015-10-15
WO2008080367A1 (fr) 2008-07-10
JP2010514708A (ja) 2010-05-06
AU2007341803A1 (en) 2008-07-10
EP2123260A1 (en) 2009-11-25
CN101209243A (zh) 2008-07-02
RU2494729C2 (ru) 2013-10-10
CU20090114A7 (es) 2011-02-24
AU2007341803A2 (en) 2009-09-03
KR20090094043A (ko) 2009-09-02
US20110002977A1 (en) 2011-01-06
AU2007341803B2 (en) 2011-08-11
KR101126629B1 (ko) 2012-03-26
JP2013177397A (ja) 2013-09-09
CA2673924C (en) 2013-10-01
EP2123260B1 (en) 2013-02-20
EP2123260A4 (en) 2010-03-17
MY150670A (en) 2014-02-28
JP6187961B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
HK1133398A1 (en) Liposome formulation of mitoxantrone and method for preparation thereof
IL262205A (en) Protein formulations and methods for their preparation
GB2455041B (en) Collagen preparation and method of isolation
EP2076558B8 (en) Composition comprising neopentasilane and method of preparing same
HK1160385A1 (zh) 製備穩定的單層脂質體混懸液的組合物和方法
ZA200900345B (en) Preparation of pharmaceutical formulations
EP2331072B8 (en) Methods and compositions for oral administration of proteins
ZA201203316B (en) Liposome of irinotecan or its hydrochloride and preparation method thereof
EP2021455A4 (en) SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
EP2405758A4 (en) METHOD AND COMPOSITIONS FOR THE LIPOSOMAL FORMULATION OF ANTIGENES AND THEIR USE
IL225961A (en) Liposomal nanoparticles and a method for their preparation
EP2152293A4 (en) PROTEIN DELIVERY COMPOSITIONS AND METHODS OF USING THE SAME
EP2080510A4 (en) METHOD FOR PRODUCING A LIPOSOME PREPARATION
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
PT1993557E (pt) Nova formulação de epoprostenol e método de fabrico da mesma
ZA200909147B (en) IM-16 crystallized solid and method of preparation thereof
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
IL192564A0 (en) Composition and method of use thereof
IL191922A0 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
ZA201101214B (en) Formulations of canfosfamide and their preparation
IL192552A0 (en) Dnt-succinate and methods of preparation thereof
GB0622341D0 (en) Novel compounds and methods for their preparation
IL190726A0 (en) Dnt-benzenesulfonate and methods of preparation thereof
IL192553A0 (en) Dnt-fumarate and methods of preparation thereof